Kevin Adam is a litigation partner in White & Case’s Boston and New York offices and a core member of the Firm’s Global Antitrust/Competition Group. Kevin is a trial lawyer who litigates complex matters at the cutting edge of antitrust and intellectual property, including class actions and competitor lawsuits involving innovation, technology, and pharmaceuticals. He also counsels global clients on a broad range of challenging competition matters, such as pricing practices, licensing and co-development agreements, government investigations, and evolving legislative and regulatory developments. Kevin is a member of the Firm’s Global Pharmaceuticals/Healthcare and Technology Industry Groups and a thought leader on antitrust issues and class actions. He has published more than thirty articles on developments in these areas over the last ten years and co-authored a book on class actions titled "Deconstructing Rule 23: A Comparison of Massachusetts and Federal Class-Action Litigation." In 2021, Kevin was selected to Law360’s Competition Editorial Advisory Board. He is also a member of the ABA Antitrust Section’s Pricing Conduct Committee Advisory Board. Kevin has an extensive pro bono practice, with a focus on criminal appellate work and wrongful convictions. He has represented criminal defendants in federal and state court, successfully overturning a number of convictions in New York’s appellate divisions and securing a jury verdict for a wrongfully convicted man in federal court in Massachusetts. He also works closely with the New England Innocence Project. Kevin graduated from Suffolk University Law School summa cum laude in 2012 and was the Editor-in-Chief of the Suffolk University Law Review. He has also completed executive-level courses in economics at the MIT Sloan School of Management and in global business and negotiation at Harvard Business School. Prior to joining the firm, Kevin worked at the First District Court of Essex County in Salem, Massachusetts and served as a research assistant for the Honorable John M. Greaney, former Associate Justice of the Supreme Judicial Court of Massachusetts.
Nominee, 2021 Antitrust Writing Awards: Business, Intellectual Property
Nominee, 2021 Antitrust Writing Awards: Business, Unilateral Conduct
Nominee, 2020 Antitrust Writing Awards: Academic, General Antitrust
Winner, 2018 Antitrust Writing Awards: Business, Intellectual Property
Nominee, 2017 Antitrust Writing Awards: Business, Intellectual Property
691
Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number of industries, including pharmaceuticals, biotech, and healthcare. In (...)
555
A new Executive Order signed by President Biden includes 72 initiatives instructing more than a dozen federal agencies, including the US Department of Justice and the Federal Trade Commission, to, according to the White House’s Fact Sheet, "promptly tackle some of the most pressing competition (...)
190
On Friday, July 9, 2021, President Biden signed Executive Order 14036, Promoting Competition in the American Economy, which includes—among 72 initiatives aimed at enhancing competition in the US—a directive encouraging the Federal Trade Commission to ban or limit employee non-compete agreements. (...)
170
Calls for changes to antitrust law, and how antitrust laws should be applied to the conduct of large technology companies, have been heating up in recent years. Now, the push for wide-scale changes to antitrust law has reached a boiling point. Indeed, President Biden’s sweeping July 9, 2021 (...)
191
The pharmaceutical industry, like the technology sector, has become as a focus of U.S. lawmakers seeking to revise competition law. In April 2021, House and Senate lawmakers introduced a package of legislation targeting conduct that supposedly prevents or slows competition from less expensive (...)
232
On April 23, 2021, President Biden signed into law two bipartisan bills aimed at reducing prescription drug prices by supporting generic and biosimilar alternatives to branded drugs. The Ensuring Innovation Act supports generic drugs by clarifying the technical qualifications for earning (...)
175
What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new (...)
142
The U.S. Court of Appeals for the First Circuit’s landmark In re: Asacol Antitrust Litigation decision holds that no class containing uninjured members can be certified unless, when moving for class certification, plaintiffs offer a manageable way for defendants to contest at trial whether their (...)
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 144
New York, NY, 10001, USA
563 Chiswick High Road
W4 3AY London, UK
